Vancouver, British Columbia – November 18th 2025 – TheNewswire - Sendero Resources Corp. (TSXV:SEND) (the “Company” or “Sendero”) announces that the "best-efforts" marketed private placement offering (the "Offering") of 4,220,000 common shares of the Company (the "Shares") at a price of C$0.95 per Share (the “Offering Price”) for gross proceeds to the Company of C$4,009,000 pursuant to the Listed Issuer Financing Exemption, previously announced on November 12, 2025, has received commitments from investors ...

Core Insights - Medical device maker Medtronic exceeded Wall Street expectations for second-quarter profit and revenue, driven by robust demand for its heart disease and diabetes devices [1] Company Performance - Medtronic reported strong financial results for the second quarter, surpassing analysts' forecasts for both profit and revenue [1] - The growth in demand for heart disease and diabetes devices significantly contributed to the company's performance [1] Industry Trends - The medical device industry is experiencing increased demand, particularly in the segments related to heart disease and diabetes management [1]

Financial Performance - Q2 revenue reached $9.0 billion, a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [2] - GAAP diluted EPS was $1.07, an 8% increase, while non-GAAP diluted EPS was $1.36, also an 8% increase, both above guidance [2] - Total reported revenue for the second quarter was $8,961 million, representing a growth of 6.6% compared to $8,403 million in the previous year [25] - Total reported net sales for the second quarter reached $8,961 million, an increase of 6.6% compared to $8,403 million in the same period last year [42] - Operating profit for the second quarter was $1,686 million, representing an increase of 5.7% from $1,595 million in the prior year [42] - Net income attributable to Medtronic was $1,374 million, up from $1,270 million, marking a growth of 8.2% [42] - Basic earnings per share (EPS) for the quarter was $1.07, compared to $0.99 in the same quarter last year, reflecting an increase of 8.1% [42] - The total reportable segments showed a year-to-date growth of 9.4%, with total sales of $8,733 million compared to $7,983 million last year [36] - Net income for the six months ended October 24, 2025, was $2,428 million, an increase of 4.3% compared to $2,327 million for the same period in 2024 [67] Segment Performance - Cardiac Ablation Solutions revenue surged 71%, with a remarkable 128% growth in the U.S., driven by the pulsed field ablation (PFA) portfolio [4] - Cardiovascular Portfolio revenue was $3.436 billion, a 10.8% increase as reported and 9.3% organic growth [9] - Neuroscience Portfolio revenue reached $2.562 billion, a 4.5% increase reported and 3.9% organic [9] - Medical Surgical Portfolio revenue was $2.171 billion, a 2.1% increase reported and 1.3% organic [9] - Cardiovascular segment revenue reached $3,436 million, a 10.8% increase from $3,102 million year-over-year [25] - Cardiac Rhythm & Heart Failure segment saw a revenue increase of 15.7%, totaling $1,825 million compared to $1,578 million in the same quarter last year [25] - Neuroscience segment revenue grew by 4.5% to $2,562 million, up from $2,451 million year-over-year [25] - The Diabetes segment revenue increased by 10.3% to $757 million from $686 million year-over-year [25] - Specialty Therapies segment experienced a slight decline of 0.9%, with revenue at $744 million compared to $737 million last year [25] Guidance and Future Outlook - The company raised FY26 organic revenue growth guidance to approximately 5.5%, up from 5.0% [10] - FY26 diluted non-GAAP EPS guidance was increased to a range of $5.62 to $5.66, reflecting a potential growth of approximately 4.5% [10] - The company continues to focus on expanding its market presence and developing new technologies across various segments [25] - The company is focusing on expanding its Cardiovascular and Diabetes segments, with ongoing investments in new product development and market expansion strategies [36] Regulatory and Product Approvals - The company received favorable National Coverage Determination from CMS for the Symplicity™ procedure, addressing a U.S. market of 18 million people [4] - The Altaviva™ device received U.S. FDA approval, targeting over 16 million people in the U.S. suffering from urge urinary incontinence [4] Cash Flow and Expenses - Medtronic incurred $91 million in accelerated amortization on certain intangible assets within the Cardiovascular Portfolio [53] - The company recognized incremental costs of $39 million related to compliance with new EU medical device regulations, considered one-time costs [56] - Research and development expenses totaled $754 million, up from $697 million, indicating a growth of 8.2% [42] - Net cash provided by operating activities was $2,013 million, up from $1,944 million year-over-year [67] - Net cash used in investing activities rose to $1,201 million, compared to $604 million in the previous year, indicating a significant increase in investment outflows [67] - Dividends to shareholders increased slightly to $1,820 million from $1,795 million, showing a modest growth in shareholder returns [67] - Cash and cash equivalents at the end of the period were $1,282 million, a decrease from $1,394 million at the end of the previous year [67] - Cash paid for income taxes was $1,394 million, up from $1,335 million, reflecting an increase in tax obligations [67] - Interest payments increased to $542 million from $513 million, indicating a rise in financing costs [67]

Core Insights - Medtronic plc reported a strong Q2 FY26 with revenue of $9.0 billion, reflecting a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [1] - The company raised its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66 [1] - Cardiac Ablation Solutions experienced significant growth of 71%, with a remarkable 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio [1] Financial Performance - GAAP diluted EPS increased by 8% to $1.07, while non-GAAP diluted EPS also rose by 8% to $1.36, both above guidance [1] - The cardiovascular segment achieved its strongest revenue growth in over a decade, excluding pandemic effects [1] Product Developments - The company received broad favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity™ procedure, targeting an addressable market of 18 million people with uncontrolled hypertension [1] - Medtronic secured U.S. FDA approval for the Altaviva™ device, aimed at treating urge urinary incontinence, which affects over 16 million people in the U.S. [1] - The Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints in the Enable Hernia Repair study and initiated the Embrace Gynecology US pivotal study [1] - The U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes [1]

Earnings Report - Medtronic plc is set to release its second-quarter earnings results on November 18, with analysts expecting earnings of $1.31 per share, an increase from $1.26 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.86 billion, compared to $8.4 billion in the previous year [1] Clinical Study Announcement - On October 8, Medtronic announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system in gynecological procedures [2] - Following this announcement, Medtronic's shares rose by 0.4% to close at $96.28 [2] Analyst Ratings and Price Targets - JP Morgan analyst Robbie Marcus maintained a Neutral rating and raised the price target from $90 to $100 [8] - Truist Securities analyst Richard Newitter maintained a Hold rating and increased the price target from $96 to $103 [8] - Stifel analyst Rick Wise maintained a Hold rating and raised the price target from $90 to $105 [8] - Citigroup analyst Joanne Wuensch maintained a Buy rating and increased the price target from $101 to $112 [8] - Argus Research analyst David Toung maintained a Buy rating and raised the price target from $105 to $115 [8]

Earnings Report - Medtronic plc is set to release its second-quarter earnings results on November 18, with analysts expecting earnings of $1.31 per share, an increase from $1.26 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.86 billion, compared to $8.4 billion in the previous year [1] Clinical Study Announcement - On October 8, Medtronic announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system in gynecological procedures [2] - Following this announcement, Medtronic's shares rose by 0.4% to close at $96.28 [2] Analyst Ratings and Price Targets - JP Morgan analyst Robbie Marcus maintained a Neutral rating and raised the price target from $90 to $100 [8] - Truist Securities analyst Richard Newitter maintained a Hold rating and increased the price target from $96 to $103 [8] - Stifel analyst Rick Wise maintained a Hold rating and raised the price target from $90 to $105 [8] - Citigroup analyst Joanne Wuensch maintained a Buy rating and increased the price target from $101 to $112 [8] - Argus Research analyst David Toung maintained a Buy rating and raised the price target from $105 to $115 [8]

Earnings Reports - Home Depot Inc. is expected to report quarterly earnings of $3.85 per share on revenue of $41.14 billion [2] - Helmerich and Payne Inc. reported a loss of 1 cent per share for the fourth quarter, with quarterly sales of $1.012 billion, exceeding the analyst consensus estimate of $973.678 million [2] - Medtronic PLC is anticipated to post quarterly earnings of $1.31 per share on revenue of $8.87 billion [2] - Aecom is expected to report quarterly earnings of $1.34 per share on revenue of $4.31 billion [2] Stock Movements - Home Depot shares fell 0.4% to $356.70 in after-hours trading [2] - Helmerich and Payne shares dipped 8.2% to $25.34 in after-hours trading [2] - Medtronic shares rose 0.1% to $96.29 in after-hours trading [2] - Aecom shares gained 0.8% to $132.99 in after-hours trading [2] Mergers and Acquisitions - Akzo Nobel N.V. and Axalta Coating Systems Ltd. agreed to an all-stock merger of equals, resulting in Axalta Coating shares jumping 13.2% to $31.90 in after-hours trading [2]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - The healthcare sector is characterized by high competition, regulation, and technical complexity, making it advisable for most investors to focus on larger companies within the industry [1] Group 1: Industry Overview - The healthcare sector often sees mergers and acquisitions, with larger companies acquiring innovations from smaller firms [2] - The regulatory burden in healthcare is significant, requiring substantial financial resources and time for new treatments to gain approval, which smaller companies often struggle to manage [3] - Post-approval, marketing a product demands considerable spending, which larger companies are better equipped to handle compared to smaller firms [4] Group 2: Company Analysis - Medtronic, with a market capitalization of $120 billion, is a leading medical device manufacturer known for its attractive dividend yield and long history of dividend growth [5][6] - Pfizer, valued at $145 billion, is a major pharmaceutical company actively working to rebuild its drug pipeline, making it a strong choice for long-term investors [5][7] - Medtronic's dividend yield is approximately 3%, with a history of 48 consecutive years of dividend increases, positioning it close to becoming a Dividend King [8]

It’s a big week for earnings this week with Nvidia and some key retail names taking center stage. This week we have Nvidia (NVDA), Home Depot (HD), Walmart (WMT), Target (TGT), Lowes (LOW), Palo Alto Networks (PANW), Medtronic (MDT) and Pdd Holdings (PDD) all reporting. Before a company reports earnings, implied volatility is usually high because the market is unsure about the outcome of the report. Speculators and hedgers create huge demand for the company’s options which increases the implied volatility ...